---
title: 'T-cell redirecting bispecific antibodies in multiple myeloma: optimal dosing-schedule
  and duration of treatment'
date: '2024-09-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39321136/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240926193914&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: T-cell redirecting bispecific antibodies (BsAbs) induce significant responses
  in heavily pretreated MM. BsAbs are currently administered in a dose-dense fashion
  until disease progression. However, continuous therapy is associated with safety
  concerns, including a high risk of infections, and high costs. In addition, chronic
  exposure to BsAbs, and thus long-term T-cell stimulation, induces T-cell exhaustion,
  which may contribute to relapse. There is increasing evidence that the strategy
  ...
disable_comments: true
---
T-cell redirecting bispecific antibodies (BsAbs) induce significant responses in heavily pretreated MM. BsAbs are currently administered in a dose-dense fashion until disease progression. However, continuous therapy is associated with safety concerns, including a high risk of infections, and high costs. In addition, chronic exposure to BsAbs, and thus long-term T-cell stimulation, induces T-cell exhaustion, which may contribute to relapse. There is increasing evidence that the strategy ...